Angiocrine Bioscience
Cellular therapies derived from engineered endothelial cells for tissue and organ regeneration
Follows are private to you and power your alerts
Updated · angiocrinebioscience.com
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2012
- Latest Form D
- $2.1M, Sep 2025
- Total capital
- $64.8M
- Federal grants
- $371K
- 2 awards · 2015
- Rank in peer group#36 of 42
- Private capital raised
- $64.2M
- 3 Form D · last Sep 2025
- 14 months since last filing
- Federal contracts
- $189K
- 1 award · Health and Human S
- Rank in Biotech#298 of 4373
- Granted patents
- 3
- 35 pending · first 2021
- Rank in peer group#2 of 42
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$2.1M
- Private capital raisedForm D · SEC · 2nd filing$58.1M
- Federal contractHealth and Human S · Igf::ot::igf "SBIR Phase I Large Scale Propagation Of Cancer Cells Using The Veravec Platform In An Automated Closed System"$189K
- Federal grantHealth and Human S · Phase I · Development of an automated Umbilical Cord Blood Hematopoietic Stem Cell expansion by endothelial cells for transplantation$186K
- Federal grantHealth and Human S · Phase I · Development of an automated Umbilical Cord Blood Hematopoietic Stem Cell expansion by endothelial cells for transplantation$186K
- Private capital raisedForm D · SEC · 1st filing$4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 42 peers
Line = medianBiotech · Platform
- Federal grantsBelow median
- Granted patents#2 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Brad Geoffrey DanielDirectorNamed in SEC Form D filings
- Claude Geoffrey Davis, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- David L ParkinsonDirectorNamed in SEC Form D filings
- Jeff JonasDirectorNamed in SEC Form D filings
- Jeffrey L PortDirectorNamed in SEC Form D filings
- Jeffrey L. Port, M.D.DirectorNamed in SEC Form D filings
Show all 12 people
- John R JaskowiakExecutive OfficerNamed in SEC Form D filings
- John Geoffrey Klacking, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- John T LomoroExecutive OfficerNamed in SEC Form D filings
- Marc CohenDirectorNamed in SEC Form D filings
- Paul FinneganExecutive Officer, DirectorNamed in SEC Form D filings
- Rick Geoffrey MurdockDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 38- PendingMethods And Compositions For Stem Cell TransplantationUSPTOApplication 19381059
- PendingEngineered Endothelial Cells Expressing An Ets Transcription FactorUSPTOApplication 19316740
- PendingEnhanced Gene Delivery MethodsUSPTOApplication 18657524
Show all 38 patent records
- Methods And Compositions For Stem Cell TransplantationSep 10, 2026 · Application 19381059Pending
- Engineered Endothelial Cells Expressing An Ets Transcription FactorAug 6, 2026 · Application 19316740Pending
- Enhanced Gene Delivery MethodsApr 10, 2025 · Application 18657524Pending
- Cryopreserved Endothelial Cell CompositionsJan 18, 2024 · Application 18041080Pending
- Methods And Compositions For Stem Cell TransplantationDec 28, 2023 · Application 18464908Pending
- Blood-brain Barrier Comprising Engineered Endothelial CellsOct 17, 2023 · US 11,786,559Granted
- Endothelial Cells For Mitigation Of Chemotherapy-induced ToxicityAug 17, 2023 · Application 18003124Pending
- Compositions And Methods For Thymic Regeneration And T-cell ReconstitutionJul 21, 2022 · Application 17614521Pending
- Engineered Endothelial Cells Expressing An Ets Transcription FactorJun 30, 2022 · Application 17194293Pending
- Engineered Endothelial Cells Expressing An Ets Transcription FactorMar 30, 2021 · US 10,961,509Granted
- Neural Cells Expressing Adenovirus E4ORF1, And Methods Of Making And Using The SameMar 16, 2021 · US 10,947,500Granted
- Enhanced Gene Delivery MethodsMay 2, 2019 · Application 16092870Pending
- Methods And Compositions For Stem Cell TransplantationAug 2, 2018 · Application 15746369Pending
- Biocompatible Implants Comprising Engineered Endothelial CellsDec 21, 2017 · Application 15536794Pending
- Enhanced Gene Delivery MethodsApplication PCTUS2017027884Pending
- Enhanced Gene Delivery MethodsApplication 62403110Pending
- Blood-brain Barrier Comrpising Engineered Endothelial CellsApplication 62393774Pending
- Methods And Compostitions For Stem Cell TransplantationApplication PCTUS2016042872Pending
- Engineered Endothelial Cells Expressing An Ets Transcription FactorApplication PCTUS2016042873Pending
- Enhanced Gene Delivery MethodsApplication 62323476Pending
- Biocompatible Implants Comprising Engineered Endothelial CellsApplication PCTUS2015066782Pending
- Methods And Compositions For Stem Cell TransplantationApplication 62194460Pending
- Engineered Endothelial Cells Expressing An Ets Transcription FactorApplication 62194466Pending
- Use Of Umbilical Vein Endothelial Cells For The Treatment Of Lung InjuryApplication 19149372Pending
- Neural Cells Expressing Adenovirus E4ORF1, And Methods Of Making And Using The SameApplication PCTUS2015038182Pending
- Endothelial Cells For Treatment Of Anal FissureApplication PCTUS2025030724Pending
- Endothelial Cells For Treatment Of Anal FissureApplication 63651344Pending
- Endothelial Cells For Treatment Of Gastrointestinal FistulaApplication PCTUS2024026897Pending
- Use Of Umbilical Vein Endothelial Cells For The Treatment Of Lung InjuryApplication PCTUS2024011983Pending
- Use Of Umbilical Vein Endothelial Cells For The Treatment Of Lung InjuryApplication 63480489Pending
- Cryopreserved Endothelial Cell CompositionsApplication PCTUS2021045388Pending
- Endothelial Cells For Mitigation Of Chemotherapy-induced ToxicityApplication PCTUS2021039224Pending
- Endothelial Cells For Mitigation Of Chemotherapy-induced ToxicityApplication 63187486Pending
- Cryopreserved Endothelial Cell CompositionsApplication 63063668Pending
- Endothelial Cells For Mitigation Of Chemotherapy-induced ToxicityApplication 63044243Pending
- Compositions And Methods For Thymic Regeneration And T-cell ReconstitutionApplication PCTUS2020034932Pending
- Compositions And Methods For Thymic Regeneration And T-cell ReconstitutionApplication 62853452Pending
- Blood-brain Barrier Comprising Engineered Endothelial CellsApplication PCTUS2017051285Pending
Related companies, and why
- Celldex TherapeuticsSimilar federal contract value in Biotech · $199K in contracts
- Aura BiosciencesSimilar federal contract value in Biotech · $198K in contracts
- GEOVAX, INC.Similar federal contract value in Biotech · $198K in contracts
- Tenax TherapeuticsSimilar federal contract value in Biotech · $185K in contracts
- CANTATA BIO LLCSimilar federal contract value in Biotech · $182K in contracts
- Ambient Biosciences, Inc.Similar federal contract value in Biotech · $180K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .